Download the Paper

ASM and the Clinical & Laboratory Standards Institute (CLSI) have drafted a white paper on the MSSA and Ceftriaxone Etest issue. The data presented in a now-retracted report were obtained using Etest Ceftriaxone strips, which are not FDA-cleared for testing of staphylococci. The white paper addresses the need for reference confirmatory testing of any new resistance seen. Current CLSI M100 guidance stating that oxacillin (cefoxitin) testing can be used for predicting the susceptibility of staphylococci to ceftriaxone can and should be used.